LOUISVILLE, Ky. — USWM (US WorldMeds), and Adamis Pharmaceuticals Corporation,  today announced the U.S. launch and availability of ZIMHI (naloxone HCL Injection, USP) 5 mg/0.5 mL. ZIMHI is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose as emergency therapy in settings where opioids may be present.

According to the Centers for Disease Control and Prevention (CDC), drug overdoses are now the leading cause of death for Americans under age 50, with more powerful synthetic opioids, like fentanyl and its analogs, responsible for the largest number of those deaths. Approximately 85% of all opioid overdose related deaths are now caused by fentanyl, fentanyl analogs, and other synthetic opioids. Drug overdoses resulted in over 100,000 deaths in the United States during the 12-month period ending April 2021, which was a 29% increase over the prior 12-month period.

“ZIMHI represents an important new tool for caregivers and patients by combining an intuitive, compact, and simple to use intramuscular device with a high dose of naloxone. Successfully treating overdoses involving fentanyl often requires multiple doses of lower-dose or intranasal naloxone products, creating an urgent need for new tools to help combat these more powerful opioids,” said P. Breckinridge Jones, Sr., CEO of US WorldMeds.

Dr. Dennis J. Carlo, President and CEO of Adamis, stated, “ZIMHI provides the highest intramuscular dose of naloxone among naloxone injection devices currently available. We are very excited to once again partner with US WorldMeds to launch ZIMHI. We believe that ZIMHI will play a pivotal role in the treatment of opioid overdose, while contributing positively to the entire community that has been impacted by the opioid epidemic.”

ZIMHI is available with discounted public interest pricing for first responders and other community health organizations, with additional information available via email to [email protected] or at zimhi.com/public-service/.

Patient accessibility is further enhanced with a co-pay program that provides ZIMHI to eligible patients for as little as $0. Most pharmacies across the country are covered through the program with savings being automatically applied.